Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Stocks Crash Hard Alongside Wall Street.

Recursion Pharmaceuticals dropped its share prices by 6.45 percent on Monday to close at $4.93 apiece as investors appeared to have booked profits following four straight days of gains.

In recent news, the company unveiled Boltz-2, touted as the next-generation AI model to predict binding affinity.

According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1.

“Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,” said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan.

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

“By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,” she added.

While we acknowledge the risk and potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.